GC509

GC509 is a dual-targeting chimeric antigen receptor T-cell (CAR-T) therapy under development using Gracell's FasTCAR platform. The therapy is designed for acute myeloid leukemia and is notable for employing the FasTCAR technology, which aims to reduce manufacturing time and enhance T cell fitness. As a dual-targeting CAR-T, GC509 is engineered to recognize two separate antigens, improving specificity and potentially reducing the risk of cancer relapse by targeting heterogeneous leukemia cell populations. Precise targets for GC509 have not been specified in publicly available summaries, but similar FasTCAR therapies from Gracell are designed to target antigens such as BCMA and CD19 in other indications.